Lorlatinib analogs manuscript is published!

Aya, Jess and Satoshi’s manuscript “Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer” is now published in Nature Cancer! This collaboration with the Pfizer lorlatinib team presents specific strategies for targeting different classes of ALK compound resistance mutations.